India’s pharma export market has been affected as India supplies medicines to more than 200 countries. Supply chain interruption not only hurts Indian producers but also creates medicine scarcity in the US, UK, and African markets that highly depend on Indian generics. From the logistics end, re-routing of cargo away from conflict-ridden corridors such as the Red Sea and Strait of Hormuz has increased freight insurance premiums, distressing Indian exporters who function on lean cost structures.
